Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RCEL 
Avita Medical Ltd (RCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: RCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.98
1 Year Target Price $7.98
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 109.47M USD | Price to earnings Ratio - | 1Y Target Price 7.98 |
Price to earnings Ratio - | 1Y Target Price 7.98 | ||
Volume (30-day avg) 4 | Beta 1.65 | 52 Weeks Range 3.35 - 14.16 | Updated Date 12/2/2025 |
52 Weeks Range 3.35 - 14.16 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When After Market | Estimate -0.41 | Actual -0.7116 |
Profitability
Profit Margin -67.06% | Operating Margin (TTM) -53.65% |
Management Effectiveness
Return on Assets (TTM) -36.33% | Return on Equity (TTM) -1746.27% |
Valuation
Trailing PE - | Forward PE 4.82 | Enterprise Value 134284510 | Price to Sales(TTM) 1.51 |
Enterprise Value 134284510 | Price to Sales(TTM) 1.51 | ||
Enterprise Value to Revenue 1.85 | Enterprise Value to EBITDA -6.17 | Shares Outstanding 30493111 | Shares Floating 30197023 |
Shares Outstanding 30493111 | Shares Floating 30197023 | ||
Percent Insiders 0.8 | Percent Institutions 16.73 |
Upturn AI SWOT
Avita Medical Ltd
Company Overview
History and Background
Avita Medical Ltd is a regenerative medicine company focused on developing and commercializing innovative products for wound care. Founded in 2000, it evolved from research into spray-on skin cells to treat burns. A key milestone was FDA approval for RECELL Autologous Cell Harvesting Device in 2018.
Core Business Areas
- Wound Care: Developing and marketing RECELL, a device that enables clinicians to create Spray-On Skinu2122 cells at the point of care for thermal burn wounds and full-thickness skin defects.
Leadership and Structure
Avita Medical Ltd. has a Board of Directors which overseas the organizations corporate strategy and direction. The company is headed by an executive leadership team, including the Chief Executive Officer, that manages day-to-day operations. The company's structure includes departments focused on R&D, sales, marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- RECELL Autologous Cell Harvesting Device: RECELL enables rapid creation of Spray-On Skinu2122 cells from a small sample of the patient's own skin. It is primarily used in burn treatment. Market share data is evolving and not precisely defined but the potential market is significant. Main competitors include traditional skin grafting methods and synthetic skin substitutes. Revenue from this product constitutes the majority of the Avita Medical Ltd's total revenue.
Market Dynamics
Industry Overview
The wound care industry is growing due to aging populations, increasing rates of diabetes and obesity, and advancements in regenerative medicine. There is a growing demand for more effective and less invasive wound treatment solutions.
Positioning
Avita Medical Ltd is positioned as an innovator in regenerative medicine, offering a solution that reduces the need for extensive skin grafting. Its competitive advantage lies in its unique technology and potential for improved patient outcomes.
Total Addressable Market (TAM)
The TAM for burn and wound care is estimated to be several billion USD. Avita Medical Ltd is positioned to capture a growing share of this market with the expansion of RECELL's applications and geographic reach.
Upturn SWOT Analysis
Strengths
- Innovative technology (RECELL)
- FDA approved product
- Potential for reduced skin grafting
- Improved patient outcomes
- Strong intellectual property protection
Weaknesses
- Reliance on a single core product
- Relatively small market share compared to established players
- High cost of goods sold
- Requires specialized training for use
- Limited commercial infrastructure
Opportunities
- Expansion into new indications (e.g., chronic wounds, trauma)
- Geographic expansion (international markets)
- Strategic partnerships with hospitals and clinics
- Development of new products using the RECELL platform
- Increased awareness and adoption of regenerative medicine
Threats
- Competition from established wound care companies
- Reimbursement challenges from healthcare payers
- Potential for technological obsolescence
- Regulatory hurdles
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MOLN.ST
- BSX
Competitive Landscape
Avita Medical Ltd has an advantage in spray on skin cell technology, and disadvantage in distribution and scale, competing against larger well-established companies.
Growth Trajectory and Initiatives
Historical Growth: Avita Medical Ltd has experienced growth driven by the adoption of RECELL and market expansion.
Future Projections: Future growth is projected to be strong, driven by expanded indications, geographic expansion, and increased awareness. Analyst estimates vary. Revenue and profitability may rise and improve during this expansion phase.
Recent Initiatives: Recent initiatives include expanding commercial infrastructure, pursuing new indications for RECELL, and forming strategic partnerships.
Summary
Avita Medical Ltd is a regenerative medicine company with an innovative burn-treatment product, RECELL. The company has high growth potential given its unique offering and market opportunity. It is still loss-making due to expenses required to scale the commercial operations and new indications in its product. Avita must manage reimbursement challenges and competition from established players to achieve its long-term goals. Management needs to be able to execute its initiatives in expanding the company revenue.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Avita Medical Ltd. company reports
- Industry reports on wound care
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avita Medical Ltd
Exchange NASDAQ | Headquaters Valencia, CA, United States | ||
IPO Launch date 2019-10-01 | Independent Non-Executive Chairman & Interim CEO Mr. Cary G. Vance | ||
Sector Healthcare | Industry Medical Devices | Full time employees 260 | Website https://avitamedical.com |
Full time employees 260 | Website https://avitamedical.com | ||
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.